Neuphoria Therapeutics Inc.
NEUP
$4.19
-$0.18-4.12%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -11.51% | -178.88% | 679.54% | -141.46% | 70.05% |
| Total Depreciation and Amortization | 0.12% | 0.12% | -0.42% | 0.24% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 31.46% | 417.73% | 153.36% | 51.73% | 5.50% |
| Change in Net Operating Assets | -16.48% | 360.31% | -95.76% | 72.62% | -153.11% |
| Cash from Operations | -5.84% | -131.30% | 441.07% | 24.25% | -47.24% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 967.80% | -75.10% | -- | -- | -99.97% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 754.66% | 45.05% | 51.16% | -103.86% |
| Cash from Financing | 361.70% | -39.38% | 1,141.67% | 50.90% | -103.19% |
| Foreign Exchange rate Adjustments | -139.31% | -41.65% | 130.72% | -299.93% | 91.16% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 80.20% | -122.29% | 439.03% | 17.15% | -208.10% |